( Samaritan Announces Positive Data in No...)Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug,Health

LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce positive results were attained with its late-stage preclinical/nonclinical testing of Caprospinol (SP-233), with well recognized in-vitro models.

Although nonclinical research results are imperfect predictors of clinical responses, laboratory animals remain the best experimental models for identifying and measuring a compound's biological activity and for predicting a drug's clinical effects. Because animal studies are performed before and during clinical studies, the term "nonclinical" is generally preferred to preclinical when discussing the full spectrum of in-vitro and non-human in-vivo tests associated with drug development. By studying a drug's dose-response characteristics, adverse and residual effects, Samaritan and the FDA gain valuable insights, as to a drug's probable action, and effect in humans.

Samaritan completed a series of in-vitro studies to determine SP-233's metabolic stability in liver microsomes. SP-233's results were positive since it was reported to be stable in all four species tested: human, dog, rat and mouse species. The metabolic stability of a drug candidate, e.g., drug substance in liver microsomes of different species, is determined in order to assess the potential of SP-233 to form undesired potentially toxicity or pharmacologically inactive metabolites.

In addition, positive results were reported where SP-233 was shown to have no CYP inhibition potential for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 suggesting that SP-233, is unlikely to cause, or alter the metabolism of co-administered drugs, and thus cause, a drug-drug interaction, which could give rise to severe side effects.

Dr. Janet Greeson, CEO of Sam
'"/>